Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Lonza expands mammalian-cell manufacturing
by Rick Mullin
May 15, 2021
| A version of this story appeared in
Volume 99, Issue 18
Credit: Lonza
Lonza's mammalian cell culture facility in Portsmouth
Citing a strong customer pipeline and increasing demand for biologic drugs, Lonza says it will invest $936 million in mammalian cell manufacturing at its plants in Visp, Switzerland, and Portsmouth, New Hampshire. In Visp, the contract manufacturer will add six 20,000 L bioreactors by 2024, at a cost of $716 million. In Portsmouth, Lonza will spend $220 million to add up to eight 2,000 L bioreactors supporting clinical-to-commercial-scale manufacturing.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter